Oncotarget
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases.The term was introduced in the inaugural Editorial,Introducing Oncotarget.
As of January 1, 2022,Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Publication Alerts
Post-Publication Promotion
Learn about ourFREE
Impact Journals, LLC is the publisher of Oncotarget:www.impactjournals.com.
Impact Journals is a member of theWellcome Trust List of Compliant Publishers.
Impact Journals is a member of theSociety for Scholarly Publishing.
On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control.This malicious action will be reported to the FBI.
Current Volume
This Month's Popular DOIs
(Crossref resolutions)
| 10.18632/ONCOTARGET.23208 |
| 10.18632/ONCOTARGET.6429 |
| 10.18632/ONCOTARGET.9859 |
| 10.18632/ONCOTARGET.13553 |
| 10.18632/ONCOTARGET.14401 |
| 10.18632/ONCOTARGET.15422 |
| 10.18632/ONCOTARGET.16407 |
| 10.18632/ONCOTARGET.19087 |
Most popular Oncotarget DOIs, measured by the number of times each DOI was successfully resolved.
Most Popular DOIs Published in 2024
(Crossref Data)
Top-10 Most Popular DOIs of 2024
(Crossref Data)
Milestones in Modern Scholarly Publishing
On August 25, 2022, the Office of Science and Technology Policy announced a new government policy legislating the immediate public release of all United States-funded research publications by 2025.Learn more here andhere.
On May 23, 2023, the Council of the European Union adopted conclusions on high-quality, transparent, open, trustworthy, and equitable scholarly publishing. The Council calls for immediate and unrestricted open access to publishing research involving public funds.Learn more.
Oncotarget.org: Blog Posts on
New & Trending Papers
Oncotarget.net: Latest Insights
From Our Authors
Volume 4, Issue 3
March 2013
About The Cover
A model of Gfi1 function in T-ALL. See Khandanpour et al.
Table of Contents
Broadcast
| Gfi1 as a regulator of p53 and a therapeutic target for ALL |
https://doi.org/10.18632/oncotarget.933 Cyrus Khandanpour, and Tarik Möröy |
| 374-375 |
| PDF | HTML | How to cite |
Editorial: Oncotarget Editorials
| Lysyl Oxidase at the Crossroads of Mesenchymal Stem Cells and Epithelial-Mesenchymal Transition |
https://doi.org/10.18632/oncotarget.919 Clémence Thomas, and Antoine E. Karnoub |
| 376-377 |
| PDF | HTML | How to cite |
Reviews
| Drug-Loaded Nanoparticle Systems And Adult Stem Cells: A Potential Marriage For The Treatment Of Malignant Glioma? |
https://doi.org/10.18632/oncotarget.937 Brenda Auffinger,Ramin Morshed,Alex Tobias,Yu Cheng,Atique U Ahmed, and Maciej S Lesniak |
| 378-396 |
| Abstract | PDF | HTML | How to cite |
| Linked-In: Design and Efficacy of Antibody Drug Conjugates in Oncology |
https://doi.org/10.18632/oncotarget.924 Jonathan Feld,Stefan K. Barta,Carolina Schinke,Ira Braunschweig,Yiyu Zhou, and Amit K. Verma |
| 397-412 |
| Abstract | PDF | HTML | How to cite |
Research Papers
| Tumorigenic potential of circulating prostate tumor cells |
https://doi.org/10.18632/oncotarget.895 Filipe LF. Carvalho,Brian W. Simons,Emmanuel S. Antonarakis,Zeshaan Rasheed,Nora Douglas,Daniela Villegas,William Matsui, and David M. Berman |
| 413-421 |
| Abstract | PDF | HTML | Supplementary Information | How to cite |
| Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone |
https://doi.org/10.18632/oncotarget.917 Miklos Jaszberenyi,Andrew V Schally,Norman L Block,Mehrdad Nadji,Irving Vidaurre,Luca Szalontay, and Ferenc G Rick |
| 422-432 |
| Abstract | PDF | HTML | How to cite |
| Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo |
https://doi.org/10.18632/oncotarget.930 Shuang Yan,Zhijie Li, and Carol J Thiele |
| 433-445 |
| Abstract | PDF | HTML | Supplementary Information | How to cite |
| The Paradox of E-Cadherin: Role in response to hypoxia in the tumor microenvironment and regulation of energy metabolism |
https://doi.org/10.18632/oncotarget.872 Khoi Chu,Kimberkey M. Boley,Ricardo Moraes,Sanford H. Barsky, and Fredika M. Robertson |
| 446-462 |
| Abstract | PDF | HTML | Supplementary Information | How to cite |
| A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal |
https://doi.org/10.18632/oncotarget.886 Filip Janku,Helen J. Huang,Laura S. Angelo, and Razelle Kurzrock |
| 463-473 |
| Abstract | PDF | HTML | Supplementary Information | How to cite |
| Nuclear DNA Methylation and Chromatin Condensation Phenotypes Are Distinct Between Normally Proliferating/Aging, Rapidly Growing/Immortal, and Senescent Cells |
https://doi.org/10.18632/oncotarget.942 Jin Ho Oh,Arkadiusz Gertych, and Jian Tajbakhsh |
| 474-493 |
| Abstract | PDF | HTML | Supplementary Information | How to cite |
Copyright © 2025 Rapamycin Press LLC dba Impact Journals